JP2003300900A - Calcium absorption promoter, promoter of crystal growth of calcium phosphate, and food and drink and fodder containing them - Google Patents
Calcium absorption promoter, promoter of crystal growth of calcium phosphate, and food and drink and fodder containing themInfo
- Publication number
- JP2003300900A JP2003300900A JP2002109199A JP2002109199A JP2003300900A JP 2003300900 A JP2003300900 A JP 2003300900A JP 2002109199 A JP2002109199 A JP 2002109199A JP 2002109199 A JP2002109199 A JP 2002109199A JP 2003300900 A JP2003300900 A JP 2003300900A
- Authority
- JP
- Japan
- Prior art keywords
- calcium
- crystal growth
- culture
- calcium phosphate
- phosphate crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 96
- 239000011575 calcium Substances 0.000 title claims abstract description 96
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 96
- 239000001506 calcium phosphate Substances 0.000 title claims abstract description 56
- 229910000389 calcium phosphate Inorganic materials 0.000 title claims abstract description 55
- 235000011010 calcium phosphates Nutrition 0.000 title claims abstract description 55
- 239000013078 crystal Substances 0.000 title claims abstract description 55
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title claims abstract description 55
- 235000013305 food Nutrition 0.000 title claims abstract description 24
- 229940124532 absorption promoter Drugs 0.000 title claims abstract description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 56
- 230000001737 promoting effect Effects 0.000 claims abstract description 56
- 238000010521 absorption reaction Methods 0.000 claims abstract description 33
- 238000002425 crystallisation Methods 0.000 claims abstract description 33
- 230000008025 crystallization Effects 0.000 claims abstract description 33
- 241000894006 Bacteria Species 0.000 claims abstract description 32
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 28
- 239000004310 lactic acid Substances 0.000 claims abstract description 28
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 28
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 17
- 241000186660 Lactobacillus Species 0.000 claims abstract description 12
- 241000194036 Lactococcus Species 0.000 claims abstract description 11
- 241000194017 Streptococcus Species 0.000 claims abstract description 11
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 18
- 244000057717 Streptococcus lactis Species 0.000 claims description 14
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 14
- 239000007952 growth promoter Substances 0.000 claims description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 239000001888 Peptone Substances 0.000 claims description 6
- 108010080698 Peptones Proteins 0.000 claims description 6
- 235000019319 peptone Nutrition 0.000 claims description 6
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- 241000520130 Enterococcus durans Species 0.000 claims description 3
- 240000001929 Lactobacillus brevis Species 0.000 claims description 3
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 3
- 244000199866 Lactobacillus casei Species 0.000 claims description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 3
- 229940017800 lactobacillus casei Drugs 0.000 claims description 3
- 241000194024 Streptococcus salivarius Species 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 8
- 241000194033 Enterococcus Species 0.000 abstract description 4
- 210000000214 mouth Anatomy 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 28
- 238000009472 formulation Methods 0.000 description 26
- 238000000034 method Methods 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 17
- 238000012360 testing method Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000002925 dental caries Diseases 0.000 description 7
- 239000005018 casein Substances 0.000 description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 6
- 235000021240 caseins Nutrition 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 235000015218 chewing gum Nutrition 0.000 description 5
- 229940112822 chewing gum Drugs 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000011812 mixed powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 108010001441 Phosphopeptides Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 235000015895 biscuits Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 235000015243 ice cream Nutrition 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102100027992 Casein kinase II subunit beta Human genes 0.000 description 2
- 101710158100 Casein kinase II subunit beta Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010027252 Trypsinogen Proteins 0.000 description 2
- 102000018690 Trypsinogen Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 235000011850 desserts Nutrition 0.000 description 2
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229920002643 polyglutamic acid Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000451942 Abutilon sonneratianum Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 101100301076 Canis lupus familiaris RBM47 gene Proteins 0.000 description 1
- 241000260546 Carpoglyphus lactis Species 0.000 description 1
- 108010038061 Chymotrypsinogen Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- HECLRDQVFMWTQS-UHFFFAOYSA-N Dicyclopentadiene Chemical compound C1C2C3CC=CC3C1C=C2 HECLRDQVFMWTQS-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102220547770 Inducible T-cell costimulator_A23L_mutation Human genes 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 241001516476 Vanda Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Non-Alcoholic Beverages (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、乳酸菌培養物の新
規な用途に関し、より具体的には、乳酸菌から得られる
カルシウム結晶化抑制作用を有する培養物を有効成分と
するカルシウム吸収促進剤及びリン酸カルシウム結晶成
長促進剤並びに菌体内培養物を含有してなる飲食物と飼
料に関する。TECHNICAL FIELD The present invention relates to a novel use of a lactic acid bacterium culture, and more specifically, a calcium absorption promoter and calcium phosphate containing, as an active ingredient, a lactic acid bacterium culture having a calcium crystallization inhibitory action. The present invention relates to foods and drinks containing a crystal growth promoter and an intracellular culture.
【0002】[0002]
【従来の技術】人体を構成する無機質の中で最も多く存
在するのはカルシウムといわれており、その99%が骨
や歯の構成に利用されており、残りの1%は各種酵素の
活性の発現や筋肉の収縮、細胞の興奮の沈静あるいは血
液凝固作用等の生命活動にとって重要な役割を演じてい
る。2. Description of the Related Art It is said that calcium is the most abundant mineral in the human body, 99% of which is used for bone and tooth formation, and the remaining 1% is the activity of various enzymes. It plays an important role in life activities such as expression, muscle contraction, cell excitement sedation or blood coagulation.
【0003】このように重要なカルシウムではあるが、
その摂取量を見てみれば、日本人に必要とされる所要量
は成人1日当たり600 mgといわれているが、厚生省
保健医療局による平成10年国民栄養調査結果報告によ
れば、実際の摂取量は568mgと必要量を下回っている
のが実状である。カルシウムの摂取不足は、骨粗鬆症、
高血圧等の重大な疾病を引き起こすことが知られてお
り、社会的問題となっている。さらに、食物として胃腸
管内に摂取されたカルシウムは、複雑な機構で腸管から
血液内に吸収されるが、カルシウム塩やカルシウム剤の
腸管内における吸収率は50%以下であり、半分以上が
吸収されずに体外に排出されるという報告もある。その
ため、腸管内でのカルシウムの吸収性を高める物質の開
発も行われている。Although it is such an important calcium,
Looking at the intake, it is said that the required amount for the Japanese is 600 mg per adult per day, but according to the 1998 National Nutrition Survey Results Report by the Ministry of Health and Health, the actual intake The actual amount is less than the required amount of 568 mg. Insufficient intake of calcium causes osteoporosis,
It is known to cause serious illness such as high blood pressure, which has become a social problem. Furthermore, calcium ingested in the gastrointestinal tract as food is absorbed into the blood from the intestine by a complicated mechanism, but the absorption rate of calcium salts and calcium agents in the intestine is 50% or less, and more than half is absorbed. There is also a report that it is excreted outside the body. Therefore, a substance that enhances the absorption of calcium in the intestinal tract is being developed.
【0004】その1つとして、カゼインホスホペプチド
(CPP)が開発されている。CPPは、カゼインにトリプシ
ンを作用させ、加水分解した分解物中に得られるホスホ
ペプチドであり、カルシウムと結合して可溶性複合体を
形成する。この為、水溶液中でカルシウムが沈殿するの
を抑制することでカルシウムを可溶化し、カルシウムの
吸収率を高めると考えられている(ジャパンフードサイ
エンス、第1巻、21〜32頁[1990年];特開昭
58−170440号公報;特開平7−241172号
公報)。しかしながら、CPPは、カゼインの酵素分解物
であるため、原料であるカゼインを酵素反応させる必要
があり、また酵素分解の副産物であるペプチドが苦味を
呈するため、飲食品へ混合する場合にはこの苦味ペプチ
ドを十分に分離する必要がある等幾つかの問題点を有し
ており、また価格も大変高価である。As one of them, casein phosphopeptide (CPP) has been developed. CPP is a phosphopeptide obtained in a hydrolyzed product by allowing trypsin to act on casein, and binds to calcium to form a soluble complex. Therefore, it is considered that calcium is solubilized by suppressing the precipitation of calcium in an aqueous solution and the absorption rate of calcium is increased (Japan Food Science, Vol. 1, pp. 21-32 [1990]). JP-A-58-170440; JP-A-7-241172). However, since CPP is an enzymatic decomposition product of casein, it is necessary to enzymatically react the raw material, casein, and the peptide, which is a by-product of enzymatic decomposition, has a bitter taste. It has some problems such as the necessity of separating the peptides sufficiently, and the price is very expensive.
【0005】ポリ-L-グルタミン酸も腸管内でカルシウ
ムの吸収率を高める作用(Biosci. Biotech. Bioche
m.、第58巻、1662〜1665頁[1994年])
を有することが知られているが、これは合成品であるた
め食品添加物として許可されておらず、安全性等のため
利用されていない。また、微生物により産生されるポリ
-γ-グルタミン酸(特開平3−30648号公報)は、
カルシウム結晶化抑制活性が低く、かつ溶液の粘度が極
めて高いため、取扱いが不便である。[0005] Poly-L-glutamic acid also acts to increase the absorption rate of calcium in the intestinal tract (Biosci. Biotech. Bioche
m., 58, 1662-1665 [1994]).
However, it is not allowed as a food additive because it is a synthetic product and is not used for safety reasons. In addition, poly produced by microorganisms
-γ-glutamic acid (JP-A-3-30648)
The calcium crystallization inhibitory activity is low and the viscosity of the solution is extremely high, which makes it inconvenient to handle.
【0006】また、カルシウムの吸収を促進する物質と
しては、骨由来のペプチド(特開平4−16165号公
報)、酪酸を基本成分とするもの(特開平4−1083
60号公報)があるが、これらは 製造上並びに利用上
の問題があり実用化には至っていない。As a substance that promotes absorption of calcium, a peptide derived from bone (JP-A-4-16165) and butyric acid as a basic component (JP-A-4-1083).
No. 60), but they have not been put to practical use because of problems in production and use.
【0007】さらに、本発明者らは、南極のヴァンダ湖
に生息している細菌の菌体から得られるタンパク質がカ
ルシウム結晶化を抑制し、これによりカルシウムの吸収
を促進する効果を有することを見出したが実用化には至
っていない(特開2000−239180号公報)。Furthermore, the present inventors have found that a protein obtained from bacterial cells of a bacterium inhabiting Lake Vanda in Antarctica has an effect of suppressing calcium crystallization and thereby promoting absorption of calcium. However, it has not been put to practical use (Japanese Patent Laid-Open No. 2000-239180).
【0008】ところで、ヒトの歯エナメル質は、リン酸
カルシウムで構成されているハイドロキシアパタイトの
結晶である。ヒト口腔内ではエナメル質のリン酸カルシ
ウムが溶解する脱灰(初期の虫歯)と、元通りに結晶化
する再石灰化現象が起り、安定な状態を保っている。し
かし、歯の表面に虫歯菌が付着し、プラークと酸を産生
すると、脱灰がさらに進み虫歯となる。虫歯予防を目的
として、初期の虫歯を修復するために 再石灰化を促進
する新規食品素材の開発が待たれている。By the way, human tooth enamel is a crystal of hydroxyapatite composed of calcium phosphate. In the human oral cavity, decalcification (early caries) in which the enamel calcium phosphate dissolves and remineralization that crystallizes as before occurs, maintaining a stable state. However, when tooth decay bacteria adhere to the surface of teeth and produce plaques and acids, decalcification proceeds further, resulting in tooth decay. With the aim of preventing dental caries, the development of new food materials that promote remineralization in order to repair early dental caries is awaited.
【0009】特開平10−158178号公報には、ラ
クトバチルス及び/又はストレプトコッカスに属する乳
酸菌を用いた発酵物がミネラル吸収促進剤としての作用
を有することが開示されている。しかしながら、この発
酵物は単にカルシウムの吸収を促進する効果のみを有し
ており、リン酸カルシウム結晶成長を促進する効果を併
せ持つことについては述べられていない。JP-A-10-158178 discloses that a fermented product using a lactic acid bacterium belonging to Lactobacillus and / or Streptococcus has an action as a mineral absorption promoter. However, this fermented product only has the effect of promoting the absorption of calcium, and it is not mentioned that it also has the effect of promoting the growth of calcium phosphate crystals.
【0010】[0010]
【発明の解決しようとする課題】本発明は、上記従来技
術の問題点を解決し、カルシウムの腸管内での結晶化を
抑制することでその吸収を促進すると共に、骨や歯のリ
ン酸カルシウム結晶成長をも促進することで、初期の虫
歯や骨粗鬆症を予防するカルシウム吸収促進/リン酸カ
ルシウム結晶成長促進剤及びこれを含有してなる飲食物
と飼料の提供を目的とするものである。DISCLOSURE OF THE INVENTION The present invention solves the above-mentioned problems of the prior art, suppresses the crystallization of calcium in the intestinal tract, promotes its absorption, and grows calcium phosphate crystal growth of bones and teeth. The present invention also aims to provide a calcium absorption promoting / calcium phosphate crystal growth promoting agent for preventing early caries and osteoporosis by promoting the above, and foods and drinks and feed containing the same.
【0011】[0011]
【課題を解決するための手段】本発明者らは上記課題を
解決する為に鋭意研究を重ねた結果、Lactococcus属、L
actobacillus属、Enterococcus属、Streptococcus属か
らなる群より選択される1種または2種以上の乳酸菌の
培養物及び/又は菌体外培養物から抽出され、たタンパ
ク質がカルシウム結晶化抑制作用とリン酸カルシウム結
晶成長促進作用との双方を有することを見出し、その知
見に基づいて本発明を完成させた。従って、腸管内での
カルシウムの吸収を促進すると共に骨や歯においてのリ
ン酸カルシウム結晶成長を促進するカルシウム吸収促進
/リン酸カルシウム結晶成長促進剤を提供することが可
能となった。[Means for Solving the Problems] As a result of intensive studies to solve the above problems, the present inventors have found that Lactococcus spp.
Proteins extracted from a culture and / or extracellular culture of one or more lactic acid bacteria selected from the group consisting of actobacillus, Enterococcus and Streptococcus, and calcium crystallization inhibitory action and calcium phosphate crystal growth The present invention was completed based on the findings that they have both a promoting action. Therefore, it has become possible to provide a calcium absorption promoting / calcium phosphate crystal growth promoting agent that promotes calcium absorption in the intestinal tract and promotes calcium phosphate crystal growth in bones and teeth.
【0012】さらに、本発明は、上記カルシウム吸収促
進/リン酸カルシウム結晶成長促進剤を飲食物並びに飼
料に含有させることで上記2つの異なる効果を有する飲
食物並びに飼料を提供する。また、それらにさらにカル
シウムが配合されている飲食物並びに飼料である。Further, the present invention provides foods and drinks having the above-mentioned two different effects by incorporating the above calcium absorption promoter / calcium phosphate crystal growth promoter into the foods and drinks. Moreover, it is a food or drink and a feed in which calcium is further added to them.
【0013】また、本発明は、Lactococcus属、Lactoba
cillus属、Enterococcus属、Streptococcus属からなる
群より選択される1種または2種以上の乳酸菌の培養物
及び/又は菌体外培養物を有効成分とするリン酸カルシ
ウム結晶成長促進剤を提供する。The present invention also relates to the genus Lactococcus, Lactoba
Disclosed is a calcium phosphate crystal growth promoter containing, as an active ingredient, a culture and / or extracellular culture of one or more lactic acid bacteria selected from the group consisting of the genus cillus, the genus Enterococcus, and the genus Streptococcus.
【0014】さらに、本発明は、上記リン酸カルシウム
結晶成長促進効果を有する飲食物並びに飼料を提供す
る。また、それらにさらにカルシウムが配合されている
飲食物並びに飼料である。Further, the present invention provides foods and drinks having the above calcium phosphate crystal growth promoting effect and feed. Moreover, it is a food or drink and a feed in which calcium is further added to them.
【0015】[0015]
【発明の実施の形態】本発明を詳細に説明すれば、本発
明者らは、カルシウムが多く含まれている醗酵バターや
チーズから分離されるLactococcus属、Lactobacillus
属、Enterococcus属、Streptococcus属の乳酸菌に、カ
ルシウム結晶化抑制作用を有することを確認した。これ
らの乳酸菌の中でも特に、Lactococcus lactis 、Lacto
bacillusacidophilus 、Lactobacillus brevis 、Lacto
bacillus delbrueckii 、Lactobacillus helveticus 、
Lactobacillus phamnosus 、Enterococcus durans 、St
reptococcus salivarius 、Lactobacillus casei は、
強いカルシウム結晶化抑制作用を持つ乳酸菌であり好ま
しい菌であった。BEST MODE FOR CARRYING OUT THE INVENTION To explain the present invention in detail, the present inventors have found that Lactococcus spp., Lactobacillus isolated from fermented butter and cheese containing a large amount of calcium.
It was confirmed that lactic acid bacteria belonging to the genera Genus Enterococcus and Streptococcus have a calcium crystallization inhibitory effect. Among these lactic acid bacteria, especially Lactococcus lactis and Lacto
bacillus acidophilus, Lactobacillus brevis, Lacto
bacillus delbrueckii, Lactobacillus helveticus,
Lactobacillus phamnosus, Enterococcus durans, St
reptococcus salivarius, Lactobacillus casei
It was a lactic acid bacterium with a strong calcium crystallization inhibitory effect and was a preferable bacterium.
【0016】本発明において、乳酸菌から得られる培養
物を調製する方法としては、上記乳酸菌をIFO(財団法
人発酵研究所)指定の803培地や804培地等で前培
養し、その後0.1%(W/V)CaCl2を含むYeast Pepton
e(YP)培地、Acetate(AM)培地、或いはLactobacillu
s(NEW)培地で、30℃または37℃で定常期になるま
で培養し培養物を得、それをさらに遠心分離することに
より菌体と培養上清液とに分離した。In the present invention, as a method for preparing a culture obtained from lactic acid bacteria, the above lactic acid bacteria are pre-cultured in 803 medium or 804 medium designated by IFO (Fermentation Research Institute), and then 0.1% ( W / V) Yeast Pepton containing CaCl 2
e (YP) medium, Acetate (AM) medium, or Lactobacillu
The culture was obtained by culturing in s (NEW) medium at 30 ° C. or 37 ° C. until it reached a stationary phase, and the culture was further centrifuged to separate the cells and the culture supernatant.
【0017】菌体外培養物を得る方法は、一般に行われ
ている方法を適宜使用することができるが、本発明では
上記培養上清液を0.45μmのフィルターで吸引濾過
し、濾液を限外濾過またはポリエチレングリコール(PE
G 20,000)を用いて濃縮し、その後蒸留水に対し
て3回透析を行う方法で処理して行った。As a method for obtaining an extracellular culture, a generally used method can be appropriately used. In the present invention, the culture supernatant is suction-filtered with a 0.45 μm filter to limit the filtrate. External filtration or polyethylene glycol (PE
G 20,000), followed by treatment with distilled water against dialysis three times.
【0018】菌体内培養物を得る方法についても、一般
に行われている菌体破砕方法等を用いることで調製でき
る。例えば、フレンチプレスやX-プレス等の加圧型細
胞破壊装置を用いる方法、ボールミルやダイノーミル等
を用いる機械的磨砕法、超音波処理法、ホモジナイザー
を用いる方法、凍結融解法、浸透圧処理法、リゾチウム
等を用いる酵素処理法が挙げられるが、それらを組み合
わせることもできる。本発明では、カルシウム結晶化抑
制作用を有する乳酸菌の培養物の有効成分がタンパク質
であると考えられるので、タンパク質の安定性、抽出効
率を考慮すれば、加圧型細胞破壊、機械的磨砕、超音波
処理、ホモジナイザー等の物理的破砕方法を用いること
が好ましい。上記菌体内培養物は、必要に応じて硫酸プ
ロタミンやストレプトマイシン硫酸塩等により核酸を除
去してもよい。さらに、培養物は、必要に応じて硫酸ア
ンモニウム等の塩析やエタノール等による有機溶剤によ
る沈殿、等電点沈殿法による分画、イオン交換、吸着、
ゲル濾過、疎水、もしくはアフィニティー等のクロマト
グラフィーを用いて精製したり、透析や濃縮過程を施し
ても良い。As for the method for obtaining the intracellular culture, it can be prepared by using a generally used cell disruption method. For example, a method using a pressure-type cell disruption device such as a French press or an X-press, a mechanical grinding method using a ball mill or a dyno mill, an ultrasonic treatment method, a method using a homogenizer, a freeze-thaw method, an osmotic treatment method, rhizotium. An enzyme treatment method using, etc. can be mentioned, but they can also be combined. In the present invention, since the active ingredient of the culture of lactic acid bacteria having a calcium crystallization inhibitory effect is considered to be a protein, considering stability of the protein and extraction efficiency, pressure-type cell disruption, mechanical grinding, It is preferable to use a physical disruption method such as sonication or a homogenizer. Nucleic acid may be removed from the above-mentioned intracellular culture by using protamine sulfate, streptomycin sulfate or the like, if necessary. Further, the culture is optionally subjected to salting out with ammonium sulfate or the like, precipitation with an organic solvent such as ethanol, fractionation by the isoelectric focusing method, ion exchange, adsorption,
It may be purified by gel filtration, hydrophobicity, or chromatography such as affinity chromatography, or subjected to a dialysis or concentration process.
【0019】[表1]乃至[表5]に、本発明で使用し
た803培地、804培地、YP(イースト・ペプトン:Y
east Peptone)培地、AM(アセテート:Acetate)培地
及びNEW(ラクトバチルス:Lactobacillus)培地の組成
を示した。[Table 1] to [Table 5] show 803 medium, 804 medium, YP (yeast peptone: Y) used in the present invention.
The composition of east Peptone) medium, AM (acetate: Acetate) medium and NEW (Lactobacillus) medium is shown.
【0020】[0020]
【表1】 [Table 1]
【0021】[0021]
【表2】 [Table 2]
【0022】[0022]
【表3】 [Table 3]
【0023】[0023]
【表4】 [Table 4]
【0024】[0024]
【表5】 [Table 5]
【0025】上記の方法によって得られた本発明の乳酸
菌の培養物は、0.5〜10.0μg/mlのタンパク質
濃度でカルシウムの結晶化を抑制し、更にリン酸カルシ
ウムの結晶成長を促進するすることが認められたので、
カルシウム吸収促進剤のみならず、リン酸カルシウムの
結晶成長促進剤として有用であることが判明した。The culture of the lactic acid bacterium of the present invention obtained by the above method is capable of suppressing the crystallization of calcium at a protein concentration of 0.5 to 10.0 μg / ml and further promoting the crystal growth of calcium phosphate. Was recognized,
It was found to be useful not only as a calcium absorption promoter but also as a crystal growth promoter for calcium phosphate.
【0026】その結果、本発明の乳酸菌の培養物は、カ
ルシウムの吸収促進を目的として骨粗鬆症の予防や治療
に使用したり、リン酸カルシウムの結晶成長を目的とし
て歯の再石灰化を促進して初期の虫歯の予防や治療に使
用することができる。As a result, the culture of the lactic acid bacterium of the present invention is used for the prevention and treatment of osteoporosis for the purpose of promoting calcium absorption, and for promoting the remineralization of teeth for the purpose of crystal growth of calcium phosphate to promote the initial treatment. It can be used for the prevention and treatment of tooth decay.
【0027】本発明のカルシウム吸収促進剤及びリン酸
カルシウム結晶成長剤は、上記方法で調製した培養物を
そのまま使用してもよいが、一般には適当な液体担体に
溶解するかもしくは分散させ、または適当な粉末担体と
混合するかもしくはこれに吸着させ、所望する場合には
さらにこれらに乳化剤、分散剤、懸濁剤、展着剤、漫
透剤、湿潤剤、安定剤等を添加し、液剤、注射剤、カプ
セル剤、錠剤、粉剤等の製剤の形で、カルシウムの吸収
促進剤として、或いはリン酸カルシウムの結晶成長剤と
して使用することができる。As the calcium absorption enhancer and the calcium phosphate crystal growth agent of the present invention, the culture prepared by the above method may be used as it is, but generally, it is dissolved or dispersed in a suitable liquid carrier, or a suitable liquid carrier is used. Mix with powder carrier or adsorb to powder carrier, and if desired, further add emulsifier, dispersant, suspending agent, spreading agent, permeating agent, wetting agent, stabilizer, etc. It can be used as a calcium absorption enhancer or a calcium phosphate crystal growth agent in the form of a preparation such as an agent, a capsule, a tablet, and a powder.
【0028】また、本発明のカルシウム吸収促進剤及び
リン酸カルシウム結晶成長剤を含有してなる飲食物とし
ては、各種飲食物、例えば、清涼飲料水、果汁飲料、醗
酵飲料並びに牛乳等の飲料、チューインガム、キャンデ
ィ、錠菓、グミゼリー、ビスケット 並びに チョコレー
ト等の菓子、アイスクリーム、氷菓等の冷菓、ヨーグル
ト、チーズ等の乳製品、ハム、ソーセージ等の畜肉製
品、カマボコ、チクワ等の魚肉練り製品、パン、ホット
ケーキ、各種惣菜類、プリン、スープ 等があげられ
る。As the food and drink containing the calcium absorption promoter and the calcium phosphate crystal growth agent of the present invention, various foods and drinks, for example, soft drinks, fruit juice drinks, fermented drinks and drinks such as milk, chewing gum, Confectionery such as candy, tablets, gummy jelly, biscuits and chocolate, frozen desserts such as ice cream and frozen desserts, dairy products such as yogurt and cheese, meat products such as ham and sausage, fish paste products such as kamaboko and chikuwa, bread and hot cakes. , Various side dishes, pudding, soup, etc.
【0029】さらには、本発明のドッグフード、キャッ
トフード等のペットフード、家畜の餌等の飼料は、上記
カルシウム吸収促進剤、リン酸カルシウム結晶成長剤を
含有してなる飼料である。Further, pet foods such as dog foods and cat foods of the present invention, and feeds such as livestock feeds are feeds containing the above calcium absorption promoter and calcium phosphate crystal growth agent.
【0030】本発明のカルシウム吸収促進剤及びリン酸
カルシウム結晶成長剤を、特にカルシウムの吸収促進を
目的として使用する場合には、カルシウムを含有する原
料、例えば、牛乳、ヨーグルト、チーズ等の乳製品に配
合し、カルシウムを含有しない場合には、カルシウムと
共に配合することで、カルシウムの吸収促進効果を一層
促進することができる。いずれの場合においても、その
割合は、カルシウムの結晶化抑制物質(タンパク質)の
重量をカルシウムの重量の0.4%以上にすることが望
ましい。When the calcium absorption promoter and the calcium phosphate crystal growth agent of the present invention are used especially for the purpose of promoting absorption of calcium, they are blended with a raw material containing calcium, for example, dairy products such as milk, yogurt and cheese. However, when calcium is not contained, the effect of promoting absorption of calcium can be further promoted by blending it with calcium. In any case, it is desirable that the ratio be such that the weight of the calcium crystallization inhibitor (protein) is 0.4% or more of the weight of calcium.
【0031】本発明のカルシウム吸収促進剤の有効量と
しては、一概に規定することは困難であるが、経口的に
摂取する場合には特に制限はなく、腸管内においてカル
シウムの吸収促進効果を発揮するには、0.08 mg/k
g/日以上が適当であり、望ましくは0.1〜100 mg
/kg/日である。The effective dose of the calcium absorption enhancer of the present invention is difficult to define in a general manner, but it is not particularly limited when taken orally and exerts a calcium absorption enhancer effect in the intestinal tract. 0.08 mg / k
g / day or more is appropriate, preferably 0.1-100 mg
/ Kg / day.
【0032】また、リン酸カルシウム結晶成長促進を目
的とし、歯の再石灰化を促進する場合も同様に、0.0
1〜100 mg/kg/日で摂取するのが好ましい。Similarly, in the case of promoting remineralization of teeth for the purpose of promoting calcium phosphate crystal growth, 0.0
It is preferable to take 1 to 100 mg / kg / day.
【0033】[0033]
【実施例】以下に実施例及び試験例を示し、本発明をさ
らに詳細に説明する。
[実施例1]Lactococcus lactis IFO 3427株培養物
の調製
Lactococcus lactis IFO 3427株は、IFO指定の804培
地で30℃、48時間静置で前培養し、YP培地(5 l)
で30℃、定常期になるまで本培養した。菌体を除去
し、培養上清を0.45μmのフィルターで吸引濾過
し、その後限外濾過で200 mlになるまで濃縮し、蒸
留水に対して4℃で3回透析し、Lactococcuslactis IF
O 3427株培養物24.3 mgを得た。EXAMPLES The present invention will be described in more detail with reference to Examples and Test Examples. [Example 1] Preparation of culture of Lactococcus lactis IFO 3427 strain Lactococcus lactis IFO 3427 strain was pre-cultured in IFO-designated 804 medium at 30 ° C for 48 hours to prepare YP medium (5 l).
Main culture was carried out at 30 ° C. until the stationary phase was reached. The bacterial cells were removed, the culture supernatant was suction filtered with a 0.45 μm filter, then concentrated by ultrafiltration to 200 ml, dialyzed against distilled water 3 times at 4 ° C., and Lactococcus lactis IF.
24.3 mg of O 3427 strain culture was obtained.
【0034】[実施例2]Lactococcus lactis IFO 342
7株培養物の調製
実施例1で示す方法により得られたLactococcus lactis
IFO 3427株培養物の溶液をスーパーQトヨパール(Su
perQ-TOYOPEAL 650M(東ソー社))の陰イオンクロマト
グラフィー(2.6×20 cm)にて分画し、得られた
活性画分をさらにスーパーロース12(Superose 12
(アマシャム社製))ゲル濾過クロマトグラフィー
(1.6×60 cm)にて分画し、得られた活性画分をL
actococcus lactis IFO 3427株培養物とした。SDS-ポ
リアクリルアミドゲル電気泳動により分子量は34,0
00であることがわかった。[Example 2] Lactococcus lactis IFO 342
Preparation of 7-strain culture Lactococcus lactis obtained by the method described in Example 1
A solution of IFO 3427 strain culture was added to Super Q Toyopearl (Su
Fractionation was performed by anion chromatography (2.6 × 20 cm) of perQ-TOYOPEAL 650M (Tosoh Corp.), and the obtained active fraction was further superose 12 (Superose 12).
(Manufactured by Amersham)) Fractionated by gel filtration chromatography (1.6 × 60 cm), and the obtained active fraction is L
Actococcus lactis IFO 3427 strain culture was used. SDS-polyacrylamide gel electrophoresis shows a molecular weight of 34.0
It turned out to be 00.
【0035】[実施例3]Lactobacillus rhamnosus IF
O 12521株培養物の調製
実施例1で示す方法で、Lactobacillus rhamnosus IFO
12521株を、IFO指定の804培地で30℃、48時間静
置で前培養し、AM培地(5 l)で30℃、定常期になる
まで本培養した。菌体を集菌し、10 mMのトリス-塩酸
緩衝液(pH 8.7)で2回洗浄し、約2倍量の0.5
MのEDTA(pH8.0)水溶液中に懸濁させ、超音波破砕
で30秒サイクルで10分間破砕した。その後、上澄み
を4℃の蒸留水で透析し、 Lactobacillus rhamnosus I
FO 12521株培養物とした。[Example 3] Lactobacillus rhamnosus IF
Preparation of O 12521 Strain Culture By the method described in Example 1, Lactobacillus rhamnosus IFO
The 12521 strain was precultured in an IFO-designated 804 medium at 30 ° C. for 48 hours, and then precultured in an AM medium (5 l) at 30 ° C. until a stationary phase was reached. The bacterial cells were collected, washed twice with 10 mM Tris-hydrochloric acid buffer solution (pH 8.7), and washed with about 2 times 0.5 volume.
It was suspended in an aqueous solution of M in EDTA (pH 8.0) and sonicated for 10 minutes in a cycle of 30 seconds. After that, the supernatant was dialyzed against distilled water at 4 ° C to obtain Lactobacillus rhamnosus I
The FO 12521 strain culture was used.
【0036】[試験例1]カルシウム結晶化抑制効果の
測定
まず、腸管内でのカルシウム濃度を高めてカルシウムの
吸収性を高めるために、カルシウム結晶化抑制物質の検
討を行った。Test Example 1 Measurement of Calcium Crystallization Inhibitory Effect First, a calcium crystallization inhibitor was examined in order to increase the calcium concentration in the intestinal tract and enhance the absorbability of calcium.
【0037】炭酸水素ナトリウム水溶液(NaHCO3水溶
液)と塩化カルシウム水溶液(CaCl2水溶液)の反応か
らCaCO3が析出する反応(NaHCO3 + CaCl2 → CaCO3 +
HCl + NaCl)を利用して、カルシウム結晶化抑制効果
を判定した(Biochem. Biophys. Res. Comm.、110
(1)、p69〜74、1983年)。A reaction in which CaCO 3 is precipitated from the reaction of an aqueous sodium hydrogen carbonate solution (NaHCO 3 aqueous solution) and an aqueous calcium chloride solution (CaCl 2 aqueous solution) (NaHCO 3 + CaCl 2 → CaCO 3 +
HCl + NaCl) was used to determine the effect of suppressing calcium crystallization (Biochem. Biophys. Res. Comm., 110).
(1), p69-74, 1983).
【0038】すなわち、20 mM、pH8.7に調整した
炭酸水素ナトリウム水溶液(1.5ml)に、Lactococcu
s lactis IFO 3427株培養物を30μl添加し、スター
ラーで良く攪拌した。その後、20 mM、pH8.7に調
整した塩化カルシウム水溶液(1.5 ml)を添加し、
25℃において反応させた。反応過程中、波長570nm
における吸光度を経時的に測定した。その結果を図1に
示す。That is, Lactococcu was added to an aqueous sodium hydrogencarbonate solution (1.5 ml) adjusted to 20 mM and pH 8.7.
30 μl of the s lactis IFO 3427 strain culture was added, and well stirred with a stirrer. After that, an aqueous calcium chloride solution (1.5 ml) adjusted to 20 mM and pH 8.7 was added,
The reaction was carried out at 25 ° C. During the reaction process, wavelength 570nm
The absorbance at was measured over time. The result is shown in FIG.
【0039】コントロール(蒸留水)を添加した場合、
約200秒迄に急激な吸光度の上昇が観察され、約25
0秒後に最大値を示し、反応が完了した。一方、Lactoc
occus lactis IFO 3427株培養物(最終タンパク質濃
度0.8μg/ml)を添加した場合、吸光度の上昇が認
められず、完全にカルシウムの結晶化を抑制した。When a control (distilled water) is added,
A rapid increase in absorbance was observed by about 200 seconds,
The maximum value was shown after 0 seconds, and the reaction was completed. On the other hand, Lactoc
When the occus lactis IFO 3427 strain culture (final protein concentration 0.8 μg / ml) was added, no increase in absorbance was observed and calcium crystallization was completely suppressed.
【0040】また、この抽出物をプロテイナーゼK(Pro
teinase K)で処理すると、カルシウム結晶化抑制活性
の低下が認められたことから、活性の中心はタンパク質
であると推定された。Further, this extract was treated with proteinase K (Pro
teinase K), a decrease in calcium crystallization inhibitory activity was observed, suggesting that the center of activity was a protein.
【0041】[試験例2]各種乳酸菌培養物のカルシウ
ム結晶化抑制効果の比較
試験例1の結果をもとに、次に示す[式1]により、反
応200秒後の吸光度から阻害率を算出し、YP培地、AM
培地及びNEW培地で培養した各種乳酸菌を実施例1また
は実施例3の抽出方法に準じ、調製した培養物(最終タ
ンパク質濃度が0.8μg/ml)のカルシウム結晶化抑
制効果の比較試験を実施した。その結果を[表6]に示
す。[Test Example 2] Comparison of calcium crystallization inhibitory effect of various lactic acid bacterium cultures Based on the results of Test Example 1, the inhibition rate was calculated from the absorbance after 200 seconds of reaction according to the following [Formula 1]. , YP medium, AM
According to the extraction method of Example 1 or Example 3, various lactic acid bacteria cultured in the medium and NEW medium were subjected to a comparative test of the calcium crystallization inhibitory effect of the prepared culture (final protein concentration was 0.8 μg / ml). . The results are shown in [Table 6].
【0042】[0042]
【数1】 [Equation 1]
【0043】[0043]
【表6】 [Table 6]
【0044】この結果より、YP培地により培養された L
actococcus lactis IFO 3427の菌体外培養物に特に強い
効果が認められた。From these results, L cultured in YP medium was
A particularly strong effect was observed on the extracellular culture of actococcus lactis IFO 3427.
【0045】[試験例3]各種微生物培養物のカルシウ
ム結晶化抑制効果の比較
試験例2の方法に準じ、本発明の乳酸菌Lactococcus la
ctis IFO 3427(YP培地,菌体外)、 Lactobacillus he
lveticus IFO 15019(AM培地,菌体外)、Streptococcu
s salivarius IFO 13957(YP培地,菌体外)、既にカル
シウム結晶化抑制作用があることが知られている本発明
者等が特開2000−239181号公報に記載してい
る南極由来の細菌及び酵母の培養物について、カルシウ
ム結晶化抑制効果を比較検討した。その結果を[表7]
に示す。[Test Example 3] Comparative Calcium Crystallization Inhibitory Effect of Various Microorganism Cultures According to the method of Test Example 2, the lactic acid bacterium of the present invention, Lactococcus la.
ctis IFO 3427 (YP medium, extracellular), Lactobacillus he
lveticus IFO 15019 (AM medium, extracellular), Streptococcu
s salivarius IFO 13957 (YP medium, extracellular), the bacterium and yeast derived from Antarctica described in Japanese Patent Laid-Open No. 2000-239181 by the present inventors already known to have a calcium crystallization inhibitory action. The cultures of No. 1 were comparatively examined for the effect of suppressing calcium crystallization. The results are shown in [Table 7].
Shown in.
【0046】[0046]
【表7】 [Table 7]
【0047】この結果でも判かるように、本発明の乳酸
菌の培養物のカルシウム結晶化抑制効果が従来公知のも
のより顕著に優れていることから、これら乳酸菌から得
られるタンパク質もカルシウム結晶化抑制効果を有する
新規なタンパク質であると予想される。As can be seen from these results, the culture of lactic acid bacteria of the present invention has a significantly higher effect of suppressing calcium crystallization than those known in the related art. Therefore, proteins obtained from these lactic acid bacteria also have an effect of suppressing calcium crystallization. Is expected to be a novel protein having
【0048】[試験例4]Lactococcus lactis IFO 342
7の菌体外培養物の性状
そこで、本発明のLactococcus lactis IFO 3427の菌体
外培養物の性状について検討した。その結果を[表8]
に示す。[Test Example 4] Lactococcus lactis IFO 342
7. Properties of extracellular culture of 7 Therefore, the properties of the extracellular culture of Lactococcus lactis IFO 3427 of the present invention were examined. The results are shown in [Table 8].
Shown in.
【0049】[0049]
【表8】 [Table 8]
【0050】供試した乳酸菌培養物を、Proteinase Kで
処理すると、カルシウム結晶化抑制効果の低下が認めら
れたことより、カルシウム結晶化抑制物質はタンパク質
であると推定される。When the test lactic acid bacterium culture was treated with Proteinase K, the calcium crystallization-inhibiting effect was found to be low, so it is presumed that the calcium crystallization-inhibiting substance is a protein.
【0051】[試験例5]他の物質とのカルシウム結晶
化抑制効果の比較
次に、Lactococcus lactis IFO 3427株培養物(0.
8μg/ml)と他の物質、すなわち カゼインホスホペプ
チド(CPP III)(2.0μg/ml)、ポリ-L-グルタミ
ン酸(2.0μg/ml)、ポリ-γ-グルタミン酸(2.
0μg/ml)、EDTA:エチレンジアミン四酢酸(1.5
×10−4 M)、クエン酸(0.4×10−4 M)、ホス
ビチン(15μg/ml)、ヘパリン(15μg/ml)、コ
ンドロイチン硫酸C(15μg/ml)、アルブミン(10
μg/ml)、ラクトフェリン(10μg/ml)、リパーゼ
(10μg/ml)、トリプシノーゲン(10μg/ml)、
α-キモトリプシノーゲンA(10μg/ml)、α-アミラ
ーゼ(10μg/ml)、エステラーゼ(10μg/ml)に
ついてカルシウム結晶化抑制効果を比較検討した。その
結果を[表9]に示す。[Test Example 5] Calcium crystals with other substances
Comparison of anti-aging effect
Then, a Lactococcus lactis IFO 3427 strain culture (0.
8 μg / ml) and other substances, namely casein phosphopep
Cide (CPP III) (2.0 μg / ml), Poly-L-glutami
Acid (2.0 μg / ml), poly-γ-glutamic acid (2.
0 μg / ml), EDTA: ethylenediaminetetraacetic acid (1.5
× 10−4M), citric acid (0.4 × 10−4 M), Hoss
Vitin (15 μg / ml), Heparin (15 μg / ml), co
Androitin sulfate C (15 μg / ml), albumin (10
μg / ml), lactoferrin (10 μg / ml), lipase
(10 μg / ml), trypsinogen (10 μg / ml),
α-chymotrypsinogen A (10 μg / ml), α-amyla
For enzyme (10 μg / ml) and esterase (10 μg / ml)
Then, the effect of suppressing calcium crystallization was comparatively examined. That
The results are shown in [Table 9].
【0052】[0052]
【表9】 [Table 9]
【0053】[表9]に示すように、実施例1の方法に
準じ調製したLactococcus lactis IFO 3427株培養物
(最終タンパク質濃度0.8μg/ml)を添加した場
合、結晶化阻害率は100%であり、他の物質と比較し
てみると、カルシウム可溶化剤として知られるカゼイン
ホスホペプチド(CPP III)で62.8%、ポリ-L-グル
タミン酸(シグマ社製;No. P-4886、ナトリウム塩)で
59.4%、納豆より抽出しエタノール沈殿して精製さ
れたポリ-γ-グルタミン酸で49.0%の阻害率であっ
た。EDTAやクエン酸のようなキレート剤ではそれぞれ1
4.4%と24.5%の阻害率であり、また、炭酸カル
シウムの結晶化を阻害すると報告されているホスビチン
は30.1%の阻害率であった。その他、リンタンパク
質や酵素類を添加しても大きな結晶化阻害効果は観察さ
れなかった。本発明のLactococcus lactis IFO 3427株
より抽出したタンパク質は低濃度で著しくカルシウム
の結晶化を阻害した。As shown in [Table 9], when the Lactococcus lactis IFO 3427 strain culture (final protein concentration 0.8 μg / ml) prepared according to the method of Example 1 was added, the crystallization inhibition rate was 100%. When compared with other substances, casein phosphopeptide (CPP III) known as a calcium solubilizer is 62.8%, poly-L-glutamic acid (manufactured by Sigma; No. P-4886, sodium). (Salt) was 59.4%, and poly-γ-glutamic acid extracted from natto and precipitated with ethanol was purified to give an inhibition rate of 49.0%. 1 for each chelating agent such as EDTA or citric acid
The inhibition rates were 4.4% and 24.5%, and phosvitin, which was reported to inhibit crystallization of calcium carbonate, had an inhibition rate of 30.1%. In addition, no significant crystallization inhibitory effect was observed even when phosphoproteins and enzymes were added. The protein extracted from the Lactococcus lactis IFO 3427 strain of the present invention markedly inhibited calcium crystallization at a low concentration.
【0054】[試験例6]リン酸カルシウム結晶成長促
進効果の比較
次に、各種培地で培養した各種乳酸菌を実施例2の方法
に準じ、調製した培養物のリン酸カルシウム結晶成長
に対する影響について検討した。反応試験は、第二リン
酸カルシウム(DCPD)6 mgに、0.05 Mイミダゾー
ル緩衝液(pH 7.0)で希釈した実施例2の方法に準
じ調製した培養物を1.5 ml添加し、37℃で24
時間攪拌することで実施した。尚、ブランクには上記イ
ミダゾール緩衝液を用いた。0時間と24時間後の反応
溶液を0.45μmのフィルターで濾過し、濾液のリン
酸含有量をホスファC-テストワコーで測定し、リン酸カ
ルシウム結晶成長促進作用率を求めた。その結果を、
[表10]に示す。結果は、ブランクとの相対活性で求
めた。[Test Example 6] Comparison of Calcium Phosphate Crystal Growth Promoting Effect Next, according to the method of Example 2, various lactic acid bacteria cultivated in various media were examined for their effects on the calcium phosphate crystal growth. The reaction test was carried out by adding 1.5 ml of the culture prepared according to the method of Example 2 diluted with 0.05 M imidazole buffer (pH 7.0) to 6 mg of dicalcium phosphate (DCPD), 37 24 at ℃
It was carried out by stirring for an hour. The imidazole buffer solution was used as a blank. The reaction solution after 0 hours and 24 hours was filtered with a 0.45 μm filter, and the phosphoric acid content of the filtrate was measured with Phospha C-Test Wako to determine the calcium phosphate crystal growth promoting action rate. The result is
It shows in [Table 10]. The result was determined by the relative activity with the blank.
【0055】[0055]
【表10】 [Table 10]
【0056】本発明の乳酸菌の培養物は、いずれも強い
リン酸カルシウム結晶成長促進作用を示した。All the cultures of lactic acid bacteria of the present invention showed a strong calcium phosphate crystal growth promoting action.
【0057】比較的リン酸カルシウム結晶成長促進作用
を持つホスビチン、アルブミン、ラクトフェリン、リパ
ーゼ、トリプシノーゲンと比較しても、Lactococcus la
ctisIFO 3427株培養物は約2倍の効果であった。Even when compared with phosvitin, albumin, lactoferrin, lipase and trypsinogen, which have a relatively calcium phosphate crystal growth promoting action, Lactococcus la
The ctisIFO 3427 strain culture was approximately twice as effective.
【0058】下記に、本発明のカルシウム吸収促進剤及
びリン酸カルシウム結晶成長促進剤を含有した飲食物と
飼料の実施例を記載する。なお、配合量は重量%で記載
した。Hereinafter, examples of foods and drinks containing the calcium absorption promoter and the calcium phosphate crystal growth promoter of the present invention will be described. In addition, the compounding amount was described by weight%.
【0059】[実施例4]下記の処方にしたがってチュ
ーインガムを調製した。Example 4 Chewing gum was prepared according to the following formulation.
【0060】[0060]
【表11】 [Table 11]
【0061】[実施例5]下記の処方にしたがってチュ
ーインガムを調製した。Example 5 Chewing gum was prepared according to the following formulation.
【0062】[0062]
【表12】 [Table 12]
【0063】[実施例6]下記の処方にしたがって錠菓
を調製した。Example 6 Tablet confectionery was prepared according to the following formulation.
【0064】[0064]
【表13】 [Table 13]
【0065】[実施例7]下記の処方にしたがってチョ
コレートを調製した。Example 7 Chocolate was prepared according to the following formulation.
【0066】[0066]
【表14】 [Table 14]
【0067】[実施例8]下記の処方にしたがって飲料
を調製した。Example 8 A beverage was prepared according to the following formulation.
【0068】[0068]
【表15】 [Table 15]
【0069】[実施例9]下記の処方にしたがって飲料
を調製した。Example 9 A beverage was prepared according to the following formulation.
【0070】[0070]
【表16】 [Table 16]
【0071】[実施例10]下記の処方にしたがってア
イスクリームを調製した。[Example 10] An ice cream was prepared according to the following formulation.
【0072】[0072]
【表17】 [Table 17]
【0073】[実施例11]下記の処方にしたがってド
ッグフードを調製した。[Example 11] A dog food was prepared according to the following formulation.
【0074】[0074]
【表18】 [Table 18]
【0075】[実施例12]下記の処方にしたがってカ
プセル剤を調製した。Example 12 A capsule was prepared according to the following formulation.
【0076】[0076]
【表19】 [Table 19]
【0077】上記成分を均一に混合し、その混合末をハ
ードカプセルに充填した。The above components were uniformly mixed, and the mixed powder was filled in a hard capsule.
【0078】[実施例13]下記の処方にしたがって注
射剤を調製した。Example 13 An injection was prepared according to the following formulation.
【0079】[0079]
【表20】 [Table 20]
【0080】上記混合溶液をメンブランフィルターで濾
過後に再び除菌濾過を行い、その濾過液を無菌的にバイ
アルに分注し、窒素ガスを充填した後、密封して注射剤
とした。The above mixed solution was filtered through a membrane filter and then sterilized and filtered again. The filtrate was aseptically dispensed into a vial, filled with nitrogen gas, and then sealed to obtain an injection.
【0081】[実施例14]下記の処方にしたがって錠
剤を調製した。Example 14 Tablets were prepared according to the following formulation.
【0082】[0082]
【表21】 [Table 21]
【0083】上記成分を均一に混合し、その混合末を打
錠して、1錠200 mgの錠剤とした。The above ingredients were uniformly mixed, and the mixed powder was compressed into tablets to give tablets of 200 mg each.
【0084】直打用微粒No.209(メタケイ酸アルミン酸
マグネシウム20%、トウモロコシデンプン30%、乳糖50
%)Fine particles for direct hitting No. 209 (20% magnesium aluminometasilicate, 30% corn starch, 50% lactose)
%)
【0085】[実施例15]下記の処方にしたがってシ
ロップ剤を調製した。[Example 15] A syrup was prepared according to the following formulation.
【0086】[0086]
【表22】 [Table 22]
【0087】抽出タンパク質を、精製水で完全に溶解
し、単シロップを加えて混合し、シロップ剤とした。The extracted protein was completely dissolved in purified water, and a single syrup was added and mixed to obtain a syrup agent.
【0088】[実施例16]下記の処方にしたがってキ
ャンディを調製した。Example 16 A candy was prepared according to the following formulation.
【0089】[0089]
【表23】 [Table 23]
【0090】[実施例17]下記の処方にしたがってビ
スケットを調製した。Example 17 Biscuits were prepared according to the following formulation.
【0091】[0091]
【表24】 [Table 24]
【0092】上記材料を混合しドウを形成し、延展後こ
れを成型してオーブンで焙焼し、ビスケットを製造し
た。The above materials were mixed to form a dough, which was spread, molded, and then baked in an oven to produce a biscuit.
【0093】[実施例18]下記の処方にしたがってチ
ューインガムを調製した。Example 18 Chewing gum was prepared according to the following formulation.
【0094】[0094]
【表25】 [Table 25]
【0095】[実施例19]下記の処方にしたがってチ
ューインガムを調製した。Example 19 Chewing gum was prepared according to the following formulation.
【0096】[0096]
【表26】 [Table 26]
【0097】[実施例20]下記の処方にしたがって錠
菓を調製した。[Example 20] Tablet confectionery was prepared according to the following formulation.
【0098】[0098]
【表27】 [Table 27]
【0099】[実施例21]下記の処方にしたがってチ
ョコレートを調製した。Example 21 Chocolate was prepared according to the following formulation.
【0100】[0100]
【表28】 [Table 28]
【0101】[実施例22]下記の処方にしたがって飲
料を調製した。Example 22 A beverage was prepared according to the following formulation.
【0102】[0102]
【表29】 [Table 29]
【0103】[実施例23]下記の処方にしたがって飲
料を調製した。Example 23 A beverage was prepared according to the following formulation.
【0104】[0104]
【表30】 [Table 30]
【0105】[実施例24]下記の処方にしたがってア
イスクリームを調製した。[Example 24] An ice cream was prepared according to the following formulation.
【0106】[0106]
【表31】 [Table 31]
【0107】[実施例25]下記の処方にしたがって産
卵鶏用飼料を調製した。Example 25 A feed for laying chickens was prepared according to the following formulation.
【0108】[0108]
【表32】 [Table 32]
【0109】[実施例26]下記の処方にしたがってカ
プセル剤を調製した。Example 26 A capsule was prepared according to the following formulation.
【0110】[0110]
【表33】 [Table 33]
【0111】上記成分を均一に混合し、その混合末をハ
ードカプセルに充填した。The above components were uniformly mixed, and the mixed powder was filled into hard capsules.
【0112】[実施例27]下記の処方にしたがって注
射剤を調製した。[Example 27] An injection was prepared according to the following formulation.
【0113】[0113]
【表34】 [Table 34]
【0114】上記混合溶液をメンブランフィルターで濾
過後に再び除菌濾過を行い、その濾過液を無菌的にバイ
アルに分注し、窒素ガスを充填した後、密封して注射剤
とした。The above mixed solution was filtered through a membrane filter and then subjected to sterilization filtration again, and the filtered solution was aseptically dispensed into a vial, filled with nitrogen gas, and then sealed to obtain an injection.
【0115】[実施例28]下記の処方にしたがって錠
剤を調製した。Example 28 A tablet was prepared according to the following formulation.
【0116】[0116]
【表35】 [Table 35]
【0117】上記成分を均一に混合し、その混合末を打
錠して、1錠200mgの錠剤とした。The above components were uniformly mixed, and the mixed powder was compressed into tablets to give tablets of 200 mg each.
【0118】直打用微粒No.209(メタケイ酸アルミン酸
マグネシウム20%、トウモロコシデンプン30%、乳糖50
%)Fine granules for direct hits No.209 (20% magnesium aluminometasilicate, 30% corn starch, 50 lactose)
%)
【0119】[実施例29]下記の処方にしたがってシ
ロップ剤を調製した。[Example 29] A syrup was prepared according to the following formulation.
【0120】[0120]
【表36】 [Table 36]
【0121】抽出タンパク質を、精製水で完全に溶解
し、単シロップを加えて混合し、シロップ剤とした。The extracted protein was completely dissolved in purified water, and a single syrup was added and mixed to obtain a syrup agent.
【0122】[0122]
【発明の効果】本発明の乳酸菌の培養物は、カルシウム
吸収促進作用及びリン酸カルシウム結晶成長促進作用
が、従来技術で知られている物質と比較して顕著に優れ
ており、更に、乳製品に広く利用されている乳酸菌由来
物質であるので安全性も極めて高い。また、 これを含
有してなる飲食物及び飼料は、優れたカルシウムの吸収
促進効果 とリン酸カルシウム結晶成長促進効果を奏す
る。INDUSTRIAL APPLICABILITY The culture of the lactic acid bacterium of the present invention is remarkably excellent in calcium absorption promoting action and calcium phosphate crystal growth promoting action as compared with the substances known in the prior art, and further widely used in dairy products. Since it is a substance derived from lactic acid bacteria, it is extremely safe. In addition, foods and drinks containing the same exhibit excellent calcium absorption promoting effect and calcium phosphate crystal growth promoting effect.
【図1】カルシウム結晶化に対するLactococcus lactis
IFO 3427株培養物(最終タンパク質濃度0.8μg/
ml)の影響を検討したグラフである。Figure 1: Lactococcus lactis on calcium crystallization
IFO 3427 strain culture (final protein concentration 0.8 μg /
(ml) is the graph which examined the influence.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 35/74 A61P 3/14 A61P 1/02 19/10 3/14 43/00 105 19/10 A61K 37/02 43/00 105 A23L 2/00 F (72)発明者 森 潤一 大阪府東大阪市御厨栄町1丁目3番13の 702号 (72)発明者 佐伯 洋二 埼玉県さいたま市春野1丁目4番アーバン みらい東大宮3の806号 Fターム(参考) 2B150 AA06 AB20 AC05 AC06 AC07 DH04 DH14 4B017 LC03 LK01 LK15 LK21 LP01 4B018 LB08 MD20 MD86 ME05 MF01 4C084 AA02 AA03 BA05 CA04 MA16 MA23 MA34 MA35 MA37 MA47 MA66 NA14 ZA67 ZA97 ZB21 ZC21 4C087 AA01 AA02 BC55 BC56 BC57 BC61 CA32 MA16 MA23 MA34 MA35 MA37 MA47 MA66 NA14 ZA67 ZA97 ZB21 ZC21 ─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. 7 Identification code FI theme code (reference) A61K 35/74 A61P 3/14 A61P 1/02 19/10 3/14 43/00 105 19/10 A61K 37 / 02 43/00 105 A23L 2/00 F (72) Inventor Junichi Mori 1-33, Mikiteicho, Higashi-Osaka City, Osaka Prefecture 702 (72) Inventor Yoji Saeki 1-4-4 Haruno, Saitama City Urban Mirai Higashi-Omiya 3 No. 806 F term (reference) 2B150 AA06 AB20 AC05 AC06 AC07 DH04 DH14 4B017 LC03 LK01 LK15 LK21 LP01 4B018 LB08 MD20 MD86 ME05 MF01 4C084 AA02 AA03 BA05 CA04 MA16 MA23 MA34 MA35 MA37B A17 ZA21 MA47 MA21 MA47 MA67 MA14 MA14 AA01 AA02 BC55 BC56 BC57 BC61 CA32 MA16 MA23 MA34 MA35 MA37 MA47 MA66 NA14 ZA67 ZA97 ZB21 ZC21
Claims (24)
rococcus属、Streptococcus属からなる群より選択され
る1種または2種以上の乳酸菌の培養物から抽出され、
カルシウム結晶化抑制作用とリン酸カルシウム結晶成長
促進作用との双方を有するタンパク質を有効成分とする
ことを特徴とするカルシウム吸収促進/リン酸カルシウ
ム結晶成長促進剤。1. A genus Lactococcus, Lactobacillus, Ente
extracted from a culture of one or more lactic acid bacteria selected from the group consisting of genus rococcus and genus Streptococcus,
A calcium absorption promoting / calcium phosphate crystal growth promoting agent comprising a protein having both a calcium crystallization suppressing effect and a calcium phosphate crystal growth promoting effect as an active ingredient.
rococcus属、Streptococcus属からなる群より選択され
る1種または2種以上の乳酸菌の菌体外培養物から抽出
され、カルシウム結晶化抑制作用とリン酸カルシウム結
晶成長促進作用との双方を有するタンパク質を有効成分
とすることを特徴とするカルシウム吸収促進/リン酸カ
ルシウム結晶成長促進剤。2. Lactococcus, Lactobacillus, Ente
An active ingredient of a protein extracted from an extracellular culture of one or more lactic acid bacteria selected from the group consisting of genus rococcus and genus Streptococcus and having both calcium crystallization inhibitory action and calcium phosphate crystal growth promoting action A calcium absorption-promoting / calcium phosphate crystal growth-promoting agent.
427株培養物であることを特徴とする請求項1又は2記
載のカルシウム吸収促進/リン酸カルシウム結晶成長促
進剤。3. The culture is Lactococcus lactis IFO 3
The calcium absorption promoting / calcium phosphate crystal growth promoting agent according to claim 1 or 2, which is a 427 strain culture.
養物がイーストペプトン培地で培養されたことを特徴と
する請求項3記載のカルシウム吸収促進/リン酸カルシ
ウム結晶成長促進剤。4. The calcium absorption promoting / calcium phosphate crystal growth promoting agent according to claim 3, wherein the Lactococcus lactis IFO 3427 strain culture is cultured in yeast peptone medium.
13110株培養物であることを特徴とする請求項1又は2
記載のカルシウム吸収促進/リン酸カルシウム結晶成長
促進剤。5. The culture is Lactobacillus brevis IFO
The culture according to claim 1 or 2, which is a 13110 strain culture.
The calcium absorption promoter / calcium phosphate crystal growth promoter described.
培養物がラクトバチルス培地で培養されたことを特徴と
する請求項5記載のカルシウム吸収促進/リン酸カルシ
ウム結晶成長促進剤。6. The calcium absorption promoting / calcium phosphate crystal growth promoting agent according to claim 5, wherein the Lactobacillus brevis IFO 13110 strain culture is cultured in a Lactobacillus medium.
IFO 12521株培養物であることを特徴とする請求項1又
は2記載のカルシウム吸収促進/リン酸カルシウム結晶
成長促進剤。7. The culture is Lactobacillus rhamnosus
The calcium absorption promoting / calcium phosphate crystal growth promoting agent according to claim 1 or 2, which is a culture of IFO 12521 strain.
1株培養物がアセテート培地で培養されたことを特徴と
する請求項7記載のカルシウム吸収促進/リン酸カルシ
ウム結晶成長促進剤。8. The Lactobacillus rhamnosus IFO 1252
The calcium absorption promoting / calcium phosphate crystal growth promoting agent according to claim 7, wherein one strain culture is cultured in an acetate medium.
13131株培養物であることを特徴とする請求項1又は2
記載のカルシウム吸収促進/リン酸カルシウム結晶成長
促進剤。9. The culture is an Enterococcus durans IFO
It is a 13131 strain culture, The claim 1 or 2 characterized by the above-mentioned.
The calcium absorption promoter / calcium phosphate crystal growth promoter described.
株培養物がイーストペプトン培地で培養されたことを特
徴とする請求項9記載のカルシウム吸収促進/リン酸カ
ルシウム結晶成長促進剤。10. The Enterococcus durans IFO 13131
The calcium absorption promoting / calcium phosphate crystal growth promoting agent according to claim 9, wherein the strain culture is cultured in yeast peptone medium.
us IFO 13957株培養物であることを特徴とする請求項1
又は2記載のカルシウム吸収促進/リン酸カルシウム結
晶成長促進剤。11. The culture is Streptococcus salivari.
3. A culture of us IFO 13957 strain.
Alternatively, the calcium absorption promoting / calcium phosphate crystal growth promoting agent according to item 2.
3957株培養物がイーストペプトン培地で培養されたこと
を特徴とする請求項11記載のカルシウム吸収促進/リ
ン酸カルシウム結晶成長促進剤。12. The Streptococcus salivarius IFO 1
The calcium absorption promoting / calcium phosphate crystal growth promoting agent according to claim 11, wherein the 3957 strain culture is cultured in yeast peptone medium.
bsp. casei JCM 1134株培養物であることを特徴とする
請求項1又は2記載のカルシウム吸収促進/リン酸カル
シウム結晶成長促進剤。13. The culture is Lactobacillus casei Su
The calcium absorption promoter / calcium phosphate crystal growth promoter according to claim 1 or 2, which is a culture of bsp. casei JCM 1134 strain.
ei JCM 1134株培養物がイーストペプトン培地で培養さ
れたことを特徴とする請求項13記載のカルシウム吸収
促進/リン酸カルシウム結晶成長促進剤。14. The Lactobacillus casei Subsp. Cas
The calcium absorption promoting / calcium phosphate crystal growth promoting agent according to claim 13, wherein the culture of the ei JCM 1134 strain is cultured in yeast peptone medium.
ルシウム吸収促進/リン酸カルシウム結晶成長促進剤を
含有してなる飲食物。15. A food or drink comprising the calcium absorption promoting / calcium phosphate crystal growth promoting agent according to claim 1.
ルシウム吸収促進/リン酸カルシウム結晶成長促進剤を
含有してなる飼料。16. A feed comprising the calcium absorption promoting / calcium phosphate crystal growth promoting agent according to any one of claims 1 to 14.
とを特徴とする請求項15記載の飲食物。17. The food or drink according to claim 15, further comprising calcium.
とを特徴とする請求項16記載の飼料。18. The feed according to claim 16, which further contains calcium.
terococcus属、Streptococcus属からなる群より選択さ
れる1種または2種以上の乳酸菌の培養物を有効成分と
することを特徴とするリン酸カルシウム結晶成長促進
剤。19. Lactococcus, Lactobacillus, En
A calcium phosphate crystal growth promoter, which comprises a culture of one or more lactic acid bacteria selected from the group consisting of the genus terococcus and the genus Streptococcus as an active ingredient.
terococcus属、Streptococcus属からなる群より選択さ
れる1種または2種以上の乳酸菌の菌体外培養物を有効
成分とすることを特徴とするリン酸カルシウム結晶成長
促進剤。20. Lactococcus, Lactobacillus, En
A calcium phosphate crystal growth promoter, which comprises an extracellular culture of one or more lactic acid bacteria selected from the group consisting of the genus terococcus and the genus Streptococcus as an active ingredient.
カルシウム結晶成長促進剤を含有してなる飲食物。21. A food or drink containing the calcium phosphate crystal growth promoter according to claim 19 or 20.
カルシウム結晶成長促進剤を含有してなる飼料。22. A feed comprising the calcium phosphate crystal growth promoting agent according to claim 19 or 20.
とを特徴とする請求項21記載の飲食物。23. The food or drink according to claim 21, further comprising calcium.
とを特徴とする請求項22記載の飼料。24. The feed according to claim 22, further comprising calcium.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002109199A JP4268785B2 (en) | 2002-04-11 | 2002-04-11 | Calcium absorption promoter and calcium phosphate crystal growth promoter |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002109199A JP4268785B2 (en) | 2002-04-11 | 2002-04-11 | Calcium absorption promoter and calcium phosphate crystal growth promoter |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2003300900A true JP2003300900A (en) | 2003-10-21 |
JP4268785B2 JP4268785B2 (en) | 2009-05-27 |
Family
ID=29392725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002109199A Expired - Fee Related JP4268785B2 (en) | 2002-04-11 | 2002-04-11 | Calcium absorption promoter and calcium phosphate crystal growth promoter |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4268785B2 (en) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01128741A (en) * | 1987-11-12 | 1989-05-22 | Kanegafuchi Chem Ind Co Ltd | Method for making breads and breads having increased flavor |
JPH0716079A (en) * | 1993-06-30 | 1995-01-20 | Kozo Asano | Fermented gelatinized marine food and its production |
JPH0970260A (en) * | 1995-06-26 | 1997-03-18 | Hayashibara Biochem Lab Inc | Rapidly fermented feed, its production and use |
JPH1042850A (en) * | 1996-08-01 | 1998-02-17 | Akita Pref Gov | Production of sparkling milk liquor drink |
JPH10158178A (en) * | 1996-11-29 | 1998-06-16 | Yakult Honsha Co Ltd | Mineral absorption enhancer and mineral enhancer |
JPH114684A (en) * | 1997-06-18 | 1999-01-12 | Kikkoman Corp | New beta-phosphoglucomutase |
JP2000239180A (en) * | 1999-02-18 | 2000-09-05 | Lotte Co Ltd | Calcium crystallization inhibitory absorption facilitative agent containing protein obtained from microbial cell body of bacterium having calcium crystallization inhibitory effect as active ingredient, and ingesta and feed comprising the same |
WO2001015715A2 (en) * | 1999-08-31 | 2001-03-08 | Societe Des Produits Nestle S.A. | Composition for maintenance of bone or dental health or treatment of bone or dental disorders |
JP2001211878A (en) * | 2000-02-04 | 2001-08-07 | National Federation Of Dairy Cooperative Associations | Method of culturing yogurt starter lactobacillus in high concentration, and method of producing yogurt from the obtained high concentration culture solution |
JP2001299276A (en) * | 2000-04-20 | 2001-10-30 | Enajikku Kk | Blood sugar depressant food |
JP2001321161A (en) * | 2000-05-17 | 2001-11-20 | Otsuka Shokuhin Kk | Low temperature sensitive variant strain of lactobacillus, plant-fermented material or fruit- fermented material obtained by using the same and method for producing them |
JP2002537313A (en) * | 1999-02-25 | 2002-11-05 | ソシエテ デ プロデユイ ネツスル ソシエテ アノニム | Milk protein hydrolyzate for bone or tooth disease |
-
2002
- 2002-04-11 JP JP2002109199A patent/JP4268785B2/en not_active Expired - Fee Related
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01128741A (en) * | 1987-11-12 | 1989-05-22 | Kanegafuchi Chem Ind Co Ltd | Method for making breads and breads having increased flavor |
JPH0716079A (en) * | 1993-06-30 | 1995-01-20 | Kozo Asano | Fermented gelatinized marine food and its production |
JPH0970260A (en) * | 1995-06-26 | 1997-03-18 | Hayashibara Biochem Lab Inc | Rapidly fermented feed, its production and use |
JPH1042850A (en) * | 1996-08-01 | 1998-02-17 | Akita Pref Gov | Production of sparkling milk liquor drink |
JPH10158178A (en) * | 1996-11-29 | 1998-06-16 | Yakult Honsha Co Ltd | Mineral absorption enhancer and mineral enhancer |
JPH114684A (en) * | 1997-06-18 | 1999-01-12 | Kikkoman Corp | New beta-phosphoglucomutase |
JP2000239180A (en) * | 1999-02-18 | 2000-09-05 | Lotte Co Ltd | Calcium crystallization inhibitory absorption facilitative agent containing protein obtained from microbial cell body of bacterium having calcium crystallization inhibitory effect as active ingredient, and ingesta and feed comprising the same |
JP2002537313A (en) * | 1999-02-25 | 2002-11-05 | ソシエテ デ プロデユイ ネツスル ソシエテ アノニム | Milk protein hydrolyzate for bone or tooth disease |
WO2001015715A2 (en) * | 1999-08-31 | 2001-03-08 | Societe Des Produits Nestle S.A. | Composition for maintenance of bone or dental health or treatment of bone or dental disorders |
JP2001211878A (en) * | 2000-02-04 | 2001-08-07 | National Federation Of Dairy Cooperative Associations | Method of culturing yogurt starter lactobacillus in high concentration, and method of producing yogurt from the obtained high concentration culture solution |
JP2001299276A (en) * | 2000-04-20 | 2001-10-30 | Enajikku Kk | Blood sugar depressant food |
JP2001321161A (en) * | 2000-05-17 | 2001-11-20 | Otsuka Shokuhin Kk | Low temperature sensitive variant strain of lactobacillus, plant-fermented material or fruit- fermented material obtained by using the same and method for producing them |
Also Published As
Publication number | Publication date |
---|---|
JP4268785B2 (en) | 2009-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004261522B2 (en) | Biologically non-degradable peptide, angiotensin converting enzyme inhibitor, drug and functional food | |
JP4172681B2 (en) | Methods for making products containing antihypertensive tripeptides | |
ES2320988T3 (en) | METHOD TO PREVENT OR RELIEF MALABSORTION SYMPTOMS THROUGH THE GASTROINTESTINAL TRACT. | |
WO2012063826A1 (en) | Bacterium lactobacillus helveticus having high proteolysis activity | |
AU2007292786B2 (en) | Agent for accelerating the increase in and/or preventing the decrease in blood adiponectin level, and visceral fat accumulation inhibitor | |
JP2007246413A (en) | Composition containing milk-originated basic protein | |
AU2010301764A1 (en) | A composition for promoting collagen production | |
JPWO2006075558A1 (en) | Egg-derived bone strengthening composition | |
Hajirostamloo | Bioactive component in milk and dairy product | |
JP2006273850A (en) | Suppression composition for lactic acid value elevation in blood, and food and drink comprising same | |
JP2004238320A (en) | Bone absorption inhibitor | |
JP2939301B2 (en) | Oral composition | |
ES2434691T3 (en) | Agent to promote adiponectin secretion and / or inhibit the decrease in adiponectin secretion | |
US20210188905A1 (en) | Combining beta-dipeptides and amino acids for optimal nutritional supplementation | |
JP2003300900A (en) | Calcium absorption promoter, promoter of crystal growth of calcium phosphate, and food and drink and fodder containing them | |
JP7372046B2 (en) | peptide | |
JP4242293B2 (en) | Composition for increasing bone strengthening and bone formation | |
CN117042761A (en) | Composition for enhancing physiological efficacy of lactic acid bacteria | |
JP6083085B2 (en) | Angiotensin converting enzyme inhibitor and use thereof | |
JP2000239180A (en) | Calcium crystallization inhibitory absorption facilitative agent containing protein obtained from microbial cell body of bacterium having calcium crystallization inhibitory effect as active ingredient, and ingesta and feed comprising the same | |
JP4716769B2 (en) | Method for producing antihypertensive agent | |
JP5292632B2 (en) | Heart failure preventive agent | |
JP2020097535A (en) | Composition for lowering blood pressure | |
Madureira et al. | Functional dairy ingredients | |
CN118901801A (en) | Preparation method, product and application of organic calcium formula milk powder for promoting bone growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040521 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070509 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20070622 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070628 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070709 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081105 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081231 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090204 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090223 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4268785 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120227 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120227 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150227 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |